NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s other current liabilities is $65M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), NAMSW shows a other current liabilities of $65M. That compares with $30M in the prior-year period — up 113.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NAMSW's other current liabilities is now $65M (was $30M) — a 113.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether NewAmsterdam Pharma Company NV - Warrants (15/11/2027) is outperforming or lagging.
Tracking NAMSW's other current liabilities over time shows whether NewAmsterdam Pharma Company NV - Warrants (15/11/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $65M That compares with $30M in the prior-year period — up 113.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this other current liabilities page, Stockcircle has NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $65M) with ownership activity and broader fundamentals.